Copeptin: Diagnostic parameter, biomarker, or both?;Copeptin - Diagnostischer parameter, biomarker, beides?

Therapeutische Umschau

Volumn 66, Issue 11, 2009, Pages 731-734

  Rutishauser, Jonas ^a  

^a Spitalzentrum   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; UNCLASSIFIED DRUG; VASOPRESSIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES INSIPIDUS; HEART FAILURE; HEART INFARCTION; HYPONATREMIA; PLASMA OSMOLALITY; PNEUMONIA; POLYDIPSIA; REVIEW; SEPSIS; SHOCK; VASOPRESSIN BLOOD LEVEL;

BIOLOGICAL MARKERS; DIABETES INSIPIDUS; GLYCOPEPTIDES; HUMANS; HYPONATREMIA; IMMUNOASSAY; PROGNOSIS; PROTEIN PRECURSORS; VASOPRESSINS; WATER-ELECTROLYTE IMBALANCE;

EID: 70350656113     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.66.11.731     Document Type: Review

References (24)

1. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. Journal of Clinical Investigation 1973; 52(9): 2340-2352
2. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52(1): 112-119. (Pubitemid 43032474)
3. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19(2): 43-49. (Pubitemid 351317895)
4. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001; 30(3): 671-94, vii.
5. Joynt RJ, Feibel JH, Sladek CM. Antidiuretic hormone levels in stroke patients. Ann Neurol 1981; 9(2): 182-184.
6. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26(12): 2500-2504. (Pubitemid 41676723)
7. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. Journal of Clinical Endocrinology & Metabolism 2006; 91(11): 4381-4386. (Pubitemid 44833413)
8. Jochberger S, Velik-Salchner C, Mayr VD, et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: a prospective, controlled study. Intensive care medicine 2008.
9. Jochberger S, Zitt M, Luckner G, et al. Postoperative vasopressin and copeptin levels in noncardiac surgery patients: a prospective controlled trial. Shock 2009; 31(2): 132-138.
10. Jochberger S, Dörler J, Luckner G, et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Critical Care Medicine 2009; 37(2): 476-482.
11. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA: The Journal of the American Medical Association 2004; 291(16): 1963-1971 (Pubitemid 38544277)
12. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355(20): 2099-2112. (Pubitemid 44749318)
13. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA: The Journal of the American Medical Association 2007; 297(12): 1332-1343. (Pubitemid 46513234)
14. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA: The Journal of the American Medical Association 2007; 297(12): 1319-1331 (Pubitemid 46513233)
15. Morgenthaler NG, Müller B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28(2): 219-226 (Pubitemid 47220835)
16. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007; 115(16): 2103-2110 (Pubitemid 46659061)
17. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131(4): 1058-1067.
18. Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37(2): 145-152. (Pubitemid 46066494)
19. Masiá M, Papassotiriou J, Morgenthaler NG, et al. Midregional pro-Atype natriuretic peptide and carboxy- terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007; 53(12): 2193-2201. (Pubitemid 350197304)
20. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Critical care (London, England) 2008; 12(1): R11. (Pubitemid 351292275)
21. Katan M, Morgenthaler NG, Dixit KC, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007; 92(7): 2640-2643. (Pubitemid 47037369)
22. Baylis PH, Heath DA. Plasma-arginine-vasopressin response to insulin-induced hypoglycaemia. Lancet 1977; 2(8035): 428-430.
23. Szinnai G, Morgenthaler N, Berneis K, et al. Changes in Plasma Copeptin, the C-Terminal Portion of Arginine Vasopressin during Water Deprivation and Excess in Healthy Subjects. Journal of Clinical Endocrinology & Metabolism 2007; 92(10): 3973-3978. (Pubitemid 47607649)
24. Fenske W, Störk S, Blechschmidt A, et al. Copeptin in the differential diagnosis of hyponatremia. Journal of Clinical Endocrinology & Metabolism 2009; 94(1): 123-129.